摘要
目的:了解该院注射用紫杉醇(白蛋白结合型)在抗肿瘤治疗中的应用情况,为临床合理用药提供参考。方法:采用美康临床药学管理系统,调取2020—2021年该院使用注射用紫杉醇(白蛋白结合型)出院患者病历,对用药情况进行回顾性分析,参考我国药品说明书、美国食品药品监督管理局批准的药品说明书以及美国国立综合癌症网络临床实践指南、中国临床肿瘤学会诊疗指南等的推荐,对患者治疗情况进行分析。结果:共329例患者使用注射用紫杉醇(白蛋白结合型)1 091例次,符合药品说明书适应证、指南和专家共识推荐使用的有227例(占69.00%),存在不合理用药情况。注射用紫杉醇(白蛋白结合型)的药品不良反应主要表现为血液系统毒性、胃肠道反应、外周神经系统反应、皮肤及肝损伤等。结论:该院注射用紫杉醇(白蛋白结合型)在临床使用中存在不合理情况,主要表现为超适应证用药、越级使用、用法与用量不适宜、溶剂不适宜、滴注时间不适宜和联合用药不适宜等。临床医师应严格把握药品说明书及参照相应指南使用注射用紫杉醇(白蛋白结合型),合理联合用药,加强不良反应管理与监测,保障安全用药。
OBJECTIVE: To investigate the clinical application of Paclitaxel for injection(albumin-bound) for cancer therapy in a hospital, and to provide reference for rational drug use. METHODS: The use of Paclitaxel for injection(albumin-bound) in medical orders of discharged patients in a hospital from 2020 to 2021 was retrospectively analyzed by using PASS PharmAssist. According to Chinese drug instructions, US Food and Drug Administration approved instructions, the recommendations of US National Comprehensive Cancer Network Clinical Practice Guidelines and Chinese Society of Clinical Oncology Diagnosis and Treatment Guidelines, the treatment of patients was analyzed and evaluated. RESULTS: A total of 329 patients used Paclitaxel for injection(albumin-bound) 1 091 times, 227 cases(69.00%) were in accordance with the indications and the recommendations of guidelines and expert consensus, and there were irrational drug use. The main adverse drug reactions of Paclitaxel for injection(albumin-bound) were hematological toxicity, gastrointestinal reactions, peripheral nervous system reactions, skin and liver injuries. CONCLUSIONS: The unreasonable use of Paclitaxel for injection(albumin-bound) in clinical practice in our hospital is mainly manifested in over-indication drug use, leapfrog use, unsuitable usage and dosage, unsuitable solvent and infusion time, inappropriate combination of drugs, etc. Clinicians should strictly grasp the drug instructions and refer to the corresponding guidelines for the use of Paclitaxel for injection(albumin-bound), use drug combination rationally, strengthen the management and monitoring of adverse drug reactions, and ensure safe drug use.
作者
张印印
朱伟南
刘洪峰
范秀英
王西勇
ZHANG Yinyin;ZHU Weinan;LIU Hongfeng;FAN Xiuying;WANG Xiyong(Dept.of Pharmacy,Suzhou Hospital of Anhui Medical University,Anhui Suzhou 234000,China;Dept.of Oncology,Suzhou Hospital of Anhui Medical University,Anhui Suzhou 234000,China)
出处
《中国医院用药评价与分析》
2022年第12期1522-1525,1529,共5页
Evaluation and Analysis of Drug-use in Hospitals of China
基金
安徽省高等学校自然科学研究项目(No.KJ2020A1145)。
